The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2021 | Beyond BCMA: GPRC5D & FcRH5
Loss of B-cell maturation antigen (BCMA) poses a large challenge, with many newer therapies having this target. Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, explains how this issue is being addressed with research, and where believes the science will take us. Specifically mentioned is the targeting of GPRC5D, FcRH5, and the use of combinatorial approaches. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.
